| 2025/08/07 | 17:46:32 | Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, AMI | |
| SEQ_NO |
4 |
Date of announcement |
2025/08/07 |
Time of announcement |
17:46:32 |
| Subject |
Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, AMI |
| Date of events |
2025/08/07
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2025/08/07
2.Source of capital increase funds:
Issuance of preferred stocks for cash capital increase
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance?GUS$2,000,130
Number of shares issued?G689,700 shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:N/A
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:N/A
7.Par value per share:US$0.0001
8.Issue price:US$2.9
9.Number of shares subscribed for by or allocated to employees:N/A
10.Number of shares publicly sold:N/A
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:100%
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:N/A
13.Rights and obligations of these newly issued shares:
The rights and obligations of the newly issued shares from this cash capital
increase are the same as those of existing preferred shares.
14.Utilization of the funds from the capital increase:
Program development requirements
15.Any other matters that need to be specified:None |
|
| 2025/08/07 | 17:41:36 | Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, Medeon International, Inc. | |
| SEQ_NO |
3 |
Date of announcement |
2025/08/07 |
Time of announcement |
17:41:36 |
| Subject |
Announcement for the issuance of new shares for cash capital increase on behalf of Medeon’s major subsidiary, Medeon International, Inc. |
| Date of events |
2025/08/07
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2025/08/07
2.Source of capital increase funds:
Issuance of common shares for cash capital increase
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance?GUS$2,000,130
Number of shares issued?G2,000,130 shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:N/A
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:N/A
7.Par value per share:US$1
8.Issue price:US$1
9.Number of shares subscribed for by or allocated to employees:N/A
10.Number of shares publicly sold:N/A
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:100%
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:N/A
13.Rights and obligations of these newly issued shares:
The rights and obligations of the newly issued shares from this
cash capital increase are the same as those of existing shares.
14.Utilization of the funds from the capital increase:
To invest in subsidiary
15.Any other matters that need to be specified:None |
|
| 2025/08/07 | 17:36:25 | Medeon’s Board of Directors approved the appointment of its Accounting Officer. | |
| SEQ_NO |
2 |
Date of announcement |
2025/08/07 |
Time of announcement |
17:36:25 |
| Subject |
Medeon’s Board of Directors approved the appointment of its Accounting Officer. |
| Date of events |
2025/08/07
|
To which item it meets |
paragraph 8 |
| Statement |
1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):Accounting Officer
2.Date of occurrence of the change:2025/08/07
3.Name, title, and resume of the previous position holder:
Javin Wang (Acting) / Assistant Manager, Medeon Biodesign, Inc.
4.Name, title, and resume of the new position holder:
Javin Wang / Manager, Medeon Biodesign, Inc.
5.Type of change (please enter: ‘resignation’,
‘position adjustment’, ‘dismissal’, ‘retirement’,
‘death’ or ‘new replacement’):new replacemen
6.Reason for the change:new replacemen
7.Effective date:2025/08/07
8.Any other matters that need to be specified:
On June 30, 2025, Medeon announced a change in its Accounting Officer.
As of August 7, 2025, the appointment of Ms. Javin Wang as the
Accounting Officer of the Company has been approved by the Audit Committee
and the Board of Directors. |
|
| 2025/08/07 | 17:31:11 | Medeon Board of Directors approved the 2025Q2 consolidated financial reports | |
| SEQ_NO |
1 |
Date of announcement |
2025/08/07 |
Time of announcement |
17:31:11 |
| Subject |
Medeon Board of Directors approved the 2025Q2 consolidated financial reports |
| Date of events |
2025/08/07
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of the board of directors submitted or approved:2025/08/07
2.Date of the audit committee approved:2025/08/07
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2025/01/01~2025/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):212,260
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):32,015
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(374,614)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(379,094)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(378,850)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(356,153)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(3.86)
11.Total assets end of the period (thousand NTD):1,417,122
12.Total liabilities end of the period
(thousand NTD):284,528
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,103,853
14.Any other matters that need to be specified:None |
|
| 2025/07/30 | 17:09:17 | Announcement of the Board of Directors Meeting Date for Approval of the Second-Quarter 2025 Financial Report | |
| SEQ_NO |
1 |
Date of announcement |
2025/07/30 |
Time of announcement |
17:09:17 |
| Subject |
Announcement of the Board of Directors Meeting Date for Approval of the Second-Quarter 2025 Financial Report |
| Date of events |
2025/07/30
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of a notice of the board of directors meeting is issued:2025/07/30
2.Expected date of the board of directors meeting is convened:2025/08/07
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors: Second-Quarter 2025
4.Any other matters that need to be specified:None |
|
| 2025/07/15 | 13:33:10 | The Company has been required by TPEx to announce the financial data according to the regulations. | |
| SEQ_NO |
1 |
Date of announcement |
2025/07/15 |
Time of announcement |
13:33:10 |
| Subject |
The Company has been required by TPEx to announce the financial data according to the regulations. |
| Date of events |
2025/07/15
|
To which item it meets |
paragraph 53 |
| Statement |
1.Date of occurrence of the event: 2025/07/15
2.Cause of occurrence:Announced as required by the TPEx
3.Financial and business information:
Unit: (NT$million)
(1) Monthly
June 2025 June 2024 YoY Change %
—————————————————————————
Sales revenue 39.246 22.097 77.61%
Loss before income tax (55.569) (79.617) 30.20%
Net Loss attributable to
Owners of the parent (52.460) (73.835) 28.95%
EPS (NT$) (0.57) (0.80) 28.75%(Losses reduced)
===========================================================================
(2)Quarterly
Q1 2025 Q1 2024 YoY Change %
—————————————————————————
Sales revenue 101.878 47.141 116.11%
Loss before income tax (190.856) (214.799) 11.15%
Net Loss attributable to
Owners of the parent (177.993) (199.827) 10.93%
EPS (NT$) (1.93) (2.17) 11.06%(Losses reduced)
===========================================================================
(3)Cumulative for the last four seasons
Latest 4 quarters accumulation
(Q2 2024 to Q1 2025)
—————————————————————————
Revenue 347.545
Loss before income tax (834.700)
Net Loss attributable to
Owners of the parent (783.678)
EPS (NT$) (8.50)
===========================================================================
4.Any material information that needs to be specified
according to Article 4 of Taipei Exchange Procedures
for Verification and Disclosure of Material Information
of Companies with TPEx Listed Securities:
Medeon has not released any material information
in the past six business days.
5.Any material information in a press conference listed
under Article 11 of Taipei Exchange Procedures for
Verification and Disclosure of Material Information of
Companies with TPEx Listed Securities:
Medeon has not held any press conferences to explain material information
in the past six business days.
6.Any other matters that need to be specified:
(1)The aforementioned financial information for June 2025 and its YOY
comparison consists in the consolidated reviewed amounts prepared by
the Company adopting the IFRS, and has not been audited (reviewed)
by CPA; it is only for reference by investors.
(2)The information for the latest quarter (Q1 2025) refers to single
quarter amounts, not cumulative amounts from the latest financial
reports, and are consolidated amounts prepared under the IFRS,
which have been audited (reviewed) by CPA; it is only for reference
by investors.
(3)The information accumulated over the last 4 quarters consists in the
consolidated amounts from Q2 2024 to Q1 2025 prepared by the Company
adopting the IFRS, and has been audited (reviewed) by CPA; it is only
for reference by investors. |
|
| 2025/07/01 | 03:20:12 | Receiving the Complaint Requesting to Attend Mediation | |
| SEQ_NO |
1 |
Date of announcement |
2025/07/01 |
Time of announcement |
03:20:12 |
| Subject |
Receiving the Complaint Requesting to Attend Mediation |
| Date of events |
2025/06/30
|
To which item it meets |
paragraph 2 |
| Statement |
1.Parties to the legal matter:
Securities and Futures Investors Protection Center (‘SFIPC’),
Jung Chin Lin, Medeon Biodesign, Inc., Wechen Co., Ltd.,
Pei-Chen Tsai, and Center Laboratories, Inc.
2.Name of the court or punishing agency of the legal matter:
Intellectual Property and Commercial Court
3.Reference/Case number of relevant documents of the legal matter:
2025 Commercial Case Mediation No. 18.
4.Date of occurrence of the event:2025/06/30
5.Details of occurrence (including the matter under dispute):
SFIPC claims for discharging Jung Chin Lin’s directorship in the Company.
6.Handling procedure:Mediation Notice Received.
7.Impact on the Company’s finance and business and projected amount:
No impact on the finance and operation of the Company.
8.Countermeasures and improvement status:
Engaging legal counsel for advice and subsequent solutions.
9.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 2
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None |
|
| 2025/06/30 | 16:46:05 | Announcement of a change in the accounting officer | |
| SEQ_NO |
1 |
Date of announcement |
2025/06/30 |
Time of announcement |
16:46:05 |
| Subject |
Announcement of a change in the accounting officer |
| Date of events |
2025/06/30
|
To which item it meets |
paragraph 8 |
| Statement |
1.Type of personnel changed (please enter:
spokesperson, acting spokesperson, important
personnel (CEO, COO, CMO, CSO, etc.), financial
officer, accounting officer, corporate governance
officer, chief information security officer,research
and development officer, internal audit officer, or
designated and non-designated representatives):Accounting Officer
2.Date of occurrence of the change:2025/06/30
3.Name, title, and resume of the previous position holder:
Tori Lin / Senior Manager, Medeon Biodesign, Inc.
4.Name, title, and resume of the new position holder:
Javin Wang (Acting) / Assistant Manager, Medeon Biodesign, Inc.
5.Type of change (please enter: ‘resignation’,
‘position adjustment’, ‘dismissal’, ‘retirement’,
‘death’ or ‘new replacement’):Resignation
6.Reason for the change:Resignation
7.Effective date:2025/06/30
8.Any other matters that need to be specified:
The appointment of the new accounting officer is subject to the approval
by the forthcoming Audit Committee and Board of Directors. |
|
| 2025/06/20 | 15:45:46 | Medeon approved to release Directors and its representatives from Non-Competition Restrictions at the Annual Shareholders’ Meeting | |
| SEQ_NO |
3 |
Date of announcement |
2025/06/20 |
Time of announcement |
15:45:46 |
| Subject |
Medeon approved to release Directors and its representatives from Non-Competition Restrictions at the Annual Shareholders' Meeting |
| Date of events |
2025/06/20
|
To which item it meets |
paragraph 21 |
| Statement |
1.Date of the shareholders’ meeting resolution:2025/06/20
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
CENTER LABORATORIES INC. ; Director
Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director
Jien Wei Yeh; Independent Director
3.Items of competitive conduct in which the officer is
permitted to engage:
Invest in or manage other companies with the same or similar scope of
business as Medeon Biodesign, Inc.
4.Period of permission to engage in the competitive conduct:
During the period of serving as director of Medeon Biodesign, Inc.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
Shares represented at the time of voting: 53,776,859 rights
Number of voting rights of shareholders present at the time of voting
Votes in favor 53,093,937 votes?APercentage of the total represented share
present 98.73%
Votes against 131,105 votes?APercentage of the total represented share
present 0.24%
Votes invalid 0 votes?APercentage of the total represented share
present 0.00%
Votes abstained 551,817 votes?APercentage of the total represented share
present 1.02%
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter ‘N/A’ below):
Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:
Director, Guangzhou Hybot Technology Co., Ltd.
8.Address of the mainland China enterprise:
Guangzhou Hybot Technology Co., Ltd.?GRoom 201-16, 2nd Floor, Building 3,
Industrial Internet Innovation Center, No. 2-1 Ketai 1st Road, Guangzhou
Private Science and Technology Park, Baiyun District, Guangzhou, China
9.Operations of the mainland China enterprise:
Guangzhou Hybot Technology Co., Ltd.?GSales of New Energy Vehicles
10.Impact on the company’s finance and business:N/A
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:None |
|
| 2025/06/20 | 15:34:06 | Announcement for the material resolutions at the 2025 Annual Shareholders’ Meeting. | |
| SEQ_NO |
2 |
Date of announcement |
2025/06/20 |
Time of announcement |
15:34:06 |
| Subject |
Announcement for the material resolutions at the 2025 Annual Shareholders’ Meeting. |
| Date of events |
2025/06/20
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2025/06/20
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2024 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:
Approval of the amendment to the Articles of Incorporation
4.Important resolutions III.Business report and financial statements:
Ratification of 2024 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:
(1) Approval of the proposal for the private placement to issue
additional common shares
(2) Approval of the release of directors or its representatives from
Non-Competition Restrictions.
7.Any other matters that need to be specified:None |
|
